Patents by Inventor Dehua Pei

Dehua Pei has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11576946
    Abstract: Described are peptides and peptide conjugates comprising CN binding motifs (CNBM) which inhibit the CN-NFAT interaction. In some embodiments, the peptides comprise: (i) CNBM; (ii) a hydrophobic, non-peptidic moiety (RH) which interacts with the hydrophobic pocket on a CN protein; (iii) a sequence -AAU1-AAU2-AAU3-AAU4-AAU5-AAU6-, wherein each of AAU2, AAU3, AAU4, AAU5, and AAU6, is, independently, optional, and each of AAU1, AAU2, AAU3, AAU4, AAU5, and AAU6 when present is independently an amino acid as defined herein; or (iv) combinations thereof. In some embodiments, RH is conjugated to the N- or C-terminus of the CNBM. In some embodiments, the sequence -AAU1-AAU2-AAU3-AAU4-AAU5-AAU6- is conjugated to the N- or C terminus of the CNBM. In some embodiments, the peptides comprise: CNBM and RH. In some embodiments. In some embodiments, the peptides comprise: CNBM and AAU1-AAU2-AAU3-AAU4-AAU5-AAU6-. In some embodiments, the peptides of the disclosure CNBM and RH.
    Type: Grant
    Filed: January 29, 2019
    Date of Patent: February 14, 2023
    Assignee: Ohio State Innovation Foundation
    Inventors: Dehua Pei, John W. Christman, Manjula Karpurapu, Patrick G. Dougherty
  • Patent number: 11510991
    Abstract: The present disclosure provides novel polypeptide conjugates. The polypeptide conjugates disclosed herein comprise a stapled peptide comprising a peptide and at least one staple which holds the peptide in an ?-helical conformation, and a cyclic cell-penetrating peptide (cCPP) conjugated, directly or indirectly, to the stapled peptide. The present disclosure demonstrates that cCPPs can be used to confer consistent cell-permeability to stapled peptides.
    Type: Grant
    Filed: October 28, 2018
    Date of Patent: November 29, 2022
    Assignee: Ohio State Innovation Foundation
    Inventor: Dehua Pei
  • Patent number: 11471535
    Abstract: The present disclosure provides novel polypeptide conjugates. The polypeptide conjugates disclosed herein comprise a stapled peptide comprising a peptide and at least one staple which holds the peptide in an ?-helical conformation, and a cyclic cell-penetrating peptide (cCPP) conjugated, directly or indirectly, to the stapled peptide. The present disclosure demonstrates that cCPPs can be used to confer consistent cell-permeability to stapled peptides.
    Type: Grant
    Filed: October 28, 2018
    Date of Patent: October 18, 2022
    Assignee: Ohio State Innovation Foundation
    Inventor: Dehua Pei
  • Publication number: 20220315631
    Abstract: The present disclosure provides novel polypeptide conjugates. The polypeptide conjugates disclosed herein comprise a stapled peptidyl beta-catenin ligand and at least one staple which holds the peptidyl ligand in an ?-helical confirmation, and a cell-penetrating peptide (CPP) conjugated, directly or indirectly, to the stapled peptide.
    Type: Application
    Filed: August 28, 2020
    Publication date: October 6, 2022
    Inventor: Dehua PEI
  • Publication number: 20220306693
    Abstract: Disclosed herein are peptides having activity as cell penetrating peptides. In some embodiments, the peptides can comprise a cell penetrating peptide moiety and beta-haripin turn creating moiety. In other embodiments, the peptides also comprise a cargo moiety.
    Type: Application
    Filed: June 3, 2022
    Publication date: September 29, 2022
    Inventors: Dehua PEI, Ziqing QIAN
  • Publication number: 20220281920
    Abstract: The present disclosure provides a large combinatorial library of cell-permeable bicyclic peptides. The bicyclic peptides described herein include the first ring consisted of randomized peptide sequences for potential binding to a target of interest while the second ring featured a family of different cell-penetrating motifs, for both cell penetration and target binding. The library was screened against the I?B kinase ?/? (IKK?/?)-binding domain of NF-?B essential modulator (NEMO), resulting in the discovery of several cell-permeable bicyclic peptides which inhibited the NEMO-IKK? interaction, thereby selectively inhibiting canonical NF-?B signaling in mammalian cells and the proliferation of cisplatin-resistant ovarian cancer cells.
    Type: Application
    Filed: May 23, 2022
    Publication date: September 8, 2022
    Inventor: Dehua PEI
  • Publication number: 20220177523
    Abstract: Disclosed herein are compounds having activity as cell penetrating peptides. In some examples, the compounds can comprise a cell penetrating peptide moiety and a cargo moiety. The cargo moiety can comprise one or more detectable moieties, one or more therapeutic moieties, one or more targeting moieties, or any combination thereof. In some examples, the cell penetrating peptide moiety is cyclic. In some examples, the cell penetrating peptide moiety and cargo moiety together are cyclic. In some examples, the cell penetrating peptide moiety is cyclic and the cargo moiety is appended to the cyclic cell penetrating peptide moiety structure. In some examples, the cargo moiety is cyclic and the cell penetrating peptide moiety is cyclic, and together they form a fused bicyclic system.
    Type: Application
    Filed: November 19, 2021
    Publication date: June 9, 2022
    Inventors: Dehua PEI, Ziqing QIAN
  • Patent number: 11352394
    Abstract: Disclosed herein are peptides having activity as cell penetrating peptides. In some embodiments, the peptides can comprise a cell penetrating peptide moiety and beta-hairpin turn creating moiety. In other embodiments, the peptides also comprise a cargo moiety.
    Type: Grant
    Filed: November 22, 2017
    Date of Patent: June 7, 2022
    Assignee: Ohio State Innovation Foundation
    Inventors: Dehua Pei, Ziqing Qian
  • Patent number: 11351222
    Abstract: Disclosed is a general, reversible bicyclization strategy to increase both the proteolytic stability and cell permeability of peptidyl drugs. A peptide drug is fused with a short cell-penetrating motif and converted into a conformationally constrained bicyclic structure through the formation of a pair of disulfide bonds. The resulting bicyclic peptide has greatly enhanced proteolytic stability as well as cell-permeability. Once inside the cell, the disulfide bonds are reduced to produce a linear, biologically active peptide. This strategy was applied to generate a cell-permeable bicyclic peptidyl inhibitor against the NEMO-IKK interaction.
    Type: Grant
    Filed: November 9, 2017
    Date of Patent: June 7, 2022
    Assignee: Ohio State Innovation Foundation
    Inventors: Dehua Pei, Ziqing Qian
  • Publication number: 20220160819
    Abstract: Disclosed is a general, reversible bicyclization strategy to increase both the proteolytic stability and cell permeability of peptidyl drugs. A peptide drug is fused with a short cell-penetrating motif and converted into a conformationally constrained bicyclic structure through the formation of a pair of disulfide bonds. The resulting bicyclic peptide has greatly enhanced proteolytic stability as well as cell-permeability. Once inside the cell, the disulfide bonds are reduced to produce a linear, biologically active peptide. This strategy was applied to generate a cell-permeable bicyclic peptidyl inhibitor against the NEMO-IKK interaction.
    Type: Application
    Filed: November 30, 2021
    Publication date: May 26, 2022
    Inventors: Dehua PEI, Ziqing QIAN
  • Patent number: 11339192
    Abstract: The present disclosure provides a large combinatorial library of cell-permeable bicyclic peptides. The bicyclic peptides described herein include the first ring consisted of randomized peptide sequences for potential binding to a target of interest while the second ring featured a family of different cell-penetrating motifs, for both cell penetration and target binding. The library was screened against the I?B kinase ?/? (IKK?/?)-binding domain of NF-?B essential modulator (NEMO), resulting in the discovery of several cell-permeable bicyclic peptides which inhibited the NEMO-IKK? interaction, thereby selectively inhibiting canonical NF-?B signaling in mammalian cells and the proliferation of cisplatin-resistant ovarian cancer cells.
    Type: Grant
    Filed: October 4, 2018
    Date of Patent: May 24, 2022
    Assignee: Ohio State Innovation Foundation
    Inventor: Dehua Pei
  • Patent number: 11266713
    Abstract: Disclosed is a general, reversible bicyclization strategy to increase both the proteolytic stability and cell permeability of peptidyl drugs. A peptide drug is fused with a short cell-penetrating motif and converted into a conformationally constrained bicyclic structure through the formation of a pair of disulfide bonds. The resulting bicyclic peptide has greatly enhanced proteolytic stability as well as cell-permeability. Once inside the cell, the disulfide bonds are reduced to produce a linear, biologically active peptide. This strategy was applied to generate a cell-permeable bicyclic peptidyl inhibitor against the NEMO-IKK interaction.
    Type: Grant
    Filed: November 9, 2017
    Date of Patent: March 8, 2022
    Assignee: Ohio State Innovation Foundation
    Inventors: Dehua Pei, Ziqing Qian
  • Publication number: 20220033787
    Abstract: Disclosed herein are compositions and methods of treating disclosure provides for compounds for use in treating Mitochondrial Neurogastrointestinal Encephalopathy Syndrome (MNGIE). In some embodiments, the compounds have cell penetrating activity and thymidine phosphorylase activity. In certain embodiments, the compounds disclosed herein comprise: a) at least one cell-penetrating peptide (CPP) moiety; and b) a thymidine phosphorylase, or an active fragment or analog thereof (TP), wherein the CPP is coupled, directly or indirectly, to TP.
    Type: Application
    Filed: October 6, 2021
    Publication date: February 3, 2022
    Inventors: Natarajan SETHURAMAN, Jason RUTH, Louis A. TARTAGLIA, Dehua PEI, Ziqing QIAN
  • Patent number: 11225506
    Abstract: Disclosed herein are compounds having activity as cell penetrating peptides. In some examples, the compounds can comprise a cell penetrating peptide moiety and a cargo moiety. The cargo moiety can comprise one or more detectable moieties, one or more therapeutic moieties, one or more targeting moieties, or any combination thereof. In some examples, the cell penetrating peptide moiety is cyclic. In some examples, the cell penetrating peptide moiety and cargo moiety together are cyclic. In some examples, the cell penetrating peptide moiety is cyclic and the cargo moiety is appended to the cyclic cell penetrating peptide moiety structure. In some examples, the cargo moiety is cyclic and the cell penetrating peptide moiety is cyclic, and together they form a fused bicyclic system.
    Type: Grant
    Filed: April 20, 2020
    Date of Patent: January 18, 2022
    Assignee: Entrada Therapeutics, Inc.
    Inventors: Dehua Pei, Ziqing Qian
  • Patent number: 11168310
    Abstract: Disclosed herein are compositions and methods of treating disclosure provides for compounds for use in treating Mitochondrial Neurogastrointestinal Encephalopathy Syndrome (MNGIE). In some embodiments, the compounds have cell penetrating activity and thymidine phosphorylase activity. In certain embodiments, the compounds disclosed herein comprise: a) at least one cell-penetrating peptide (CPP) moiety; and b) a thymidine phosphorylase, or an active fragment or analog thereof (TP), wherein the CPP is coupled, directly or indirectly, to TP.
    Type: Grant
    Filed: March 17, 2020
    Date of Patent: November 9, 2021
    Assignee: Entrada Therapeutics, Inc.
    Inventors: Natarajan Sethuraman, Jason Ruth, Lou A. Tartaglia, Dehua Pei, Ziqing Qian
  • Publication number: 20210261500
    Abstract: Disclosed are compounds that can penetrate the mitochondrial membrane and that are able to deliver cargo (e.g., therapeutic agents) specifically to the mitochondria.
    Type: Application
    Filed: May 6, 2019
    Publication date: August 26, 2021
    Applicant: Ohio State Innovation Foundation
    Inventors: Dehua PEI, George APPIAH KUBI, Ziqing QIAN
  • Publication number: 20210244824
    Abstract: The present disclosure provides for polypeptide conjugates. The polypeptide conjugates disclosed herein comprise a polyarginine peptide and a cyclic cell-penetrating peptide (cCPP) conjugated, directly or indirectly, to the polyarginine peptide. The present disclosure demonstrates that cCPPs conjugated to polyarginine peptides can be used to deliver nucleic acids to the cytosol of cells.
    Type: Application
    Filed: July 2, 2019
    Publication date: August 12, 2021
    Inventors: Dehua PEI, Marina BUYANOVA, Ziqing QIAN
  • Publication number: 20210169966
    Abstract: Described are peptides and peptide conjugates comprising CN binding motifs (CNBM) which inhibit the CN-NFAT interaction. In some embodiments, the peptides comprise: (i) CNBM; (ii) a hydrophobic, non-peptidic moiety (RH) which interacts with the hydrophobic pocket on a CN protein; (iii) a sequence -AAU1-AAU2-AAU3-AAU4-AAU5-AAU6-, wherein each of AAU2, AAU3, AAU4, AAU5, and AAU6, is, independently, optional, and each of AAU, AAU2, AAU3, AAU4, AAU5, and AAU6 when present is independently an amino acid as defined herein; or (iv) combinations thereof. In some embodiments, RH is conjugated to the N- or C-terminus of the CNBM. In some embodiments, the sequence -AAU1-AAU2-AAU3-AAU4-AAU5-AAU6- is conjugated to the N- or C terminus of the CNBM. In some embodiments, the peptides comprise: CNBM and RH. In some embodiments. In some embodiments, the peptides comprise: CNBM and AAU1-AAU2-AAU3-AAU4-AAU5-AAU6-. In some embodiments, the peptides of the disclosure CNBM and RH.
    Type: Application
    Filed: January 29, 2019
    Publication date: June 10, 2021
    Inventors: Dehua PEI, John W. CHRISTMAN, Manjula KARPURAPU, Patrick G. DOUGHERTY
  • Publication number: 20210115088
    Abstract: Anticachexin C1 inhibits the TNF?-TNF? receptor interaction. In this work, analogs of anticachexin C1 are disclosed. The resulting bicyclic peptides inhibit TNF?TNF?-induced cell death, NF-?B activation, and c-Jun N-terminal kinase (JNK) signaling in cultured mammalian cells. Methods of using the bicyclic peptide anticachexin C1 analogs to treat cancer, inflammatory disorders and immune disorders are also described.
    Type: Application
    Filed: December 29, 2020
    Publication date: April 22, 2021
    Inventor: Dehua PEI
  • Publication number: 20210070806
    Abstract: Disclosed are cell penetrating peptides and compositions comprising such peptides that can be used to deliver agents to various cell types.
    Type: Application
    Filed: May 9, 2019
    Publication date: March 11, 2021
    Inventor: Dehua PEI